Read the latest news and research breakthroughs happening at the BC Cancer Agency

“I speak about cancer. I ride my bike. I do these things because I want to change the story. I want a different ending.”
In 2008, Patrick Sullivan lost his young son Finn to an extremely rare form of cancer, rhabdomyosarcoma. A few months later, he was approached by two close friends: “They told me about this fundraising bike ride to Seattle, the Ride to Conquer Cancer. They wanted to put a team in it – and do it in honour of Finn. That was the start of Team Finn.”
Every member of Team Finn is inspired by a little boy who lived every moment of his short life to the fullest. Their distinctive pink jerseys read “Run. Jump. Bounce. Dance. Sing. Love. Smile. Ride,” words that celebrate Finn’s approach to every day.
Finn showed how to live life with courage and joy, and his example has helped Team Finn achieve extraordinary success in raising funds for the BC Cancer Foundation. In just three years, they have raised over $1 million to support cancer research. As Finn’s father says, “Doctors couldn’t change Finn’s story. ‘Incurable’ was his ending. If I could change that for somebody else, then every moment of time is worth it.”

flyout blocks
flyout blocks
Your donations support innovative cancer research and compassionate enhancements to patient care.
flyout blocks
Participate or donate to a fundraising event to support breakthrough cancer research in BC.
flyout blocks
See how your donations are being used to enable the great work at the BC Cancer Agency to continue.
You are here
Scientists discover first breast cancer 'oncogene' for five years
Dr. Sam Aparicio, the Agency’s head of breast cancer research, co-led a UK-based study that discovered a new cancer-causing gene, ZNF703, that when overactive, triggers the development of a particularly aggressive type of breast cancer. Patients could be tested for ZNF703 over activity, so their treatment could be tailored accordingly, and larger studies could pave the way for developing treatments that specifically target the gene. Testing for ZNF703 activity could also help reveal if patients are likely to respond to treatment, in the same way that testing for Her2 gene activity in breast cancer patients is used to reveal if she may benefit from Herceptin.







